A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa

Site 59-102, Tbilisi

Site 59-104, Tbilisi

Site 59-103, Tbilisi

Site 59-105, Tbilisi

Site 59-107, Tbilisi

Site 59-106, Batumi

Site 10-105, Norfolk

Site 10-113, Greenville

Site 10-110, Sandy Springs

Site 10-109, Coral Gables

Site 10-111, Tampa

Site 10-107, Largo

Site 10-108, Birmingham

Site 10-101, Fort Gratiot

Site 10-118, Houston

Site 10-117, San Antonio

Site 10-112, Pflugerville

Site 10-119, Northridge

Site 10-104, Fountain Valley

Site 10-102, Sacramento

Site 10-106, Spokane

Site 10-103, Portsmouth

Site 10-115, Warwick

Site 11-106, Calgary

Site 11-103, Cobourg

Site 11-102, Markham

Site 11-105, Québec

Site 11-101, Saint-Jérôme

Site 30-107, Krakow

Site 30-104, Rzeszów

Site 30-108, Katowice

Site 30-103, Ossy

Site 30-109, Lodz

Site 30-106, Olsztyn